Research advances on chemotherapy and targeted therapy of pediatric ⁃ type low ⁃ grade glioma
Abstract
Pediatric ⁃ type low ⁃ grade glioma (pLGG) is the most common central nervous system tumor in children, and most pLGG exhibits non ⁃invasive clinical behavior with a good prognosis. Total surgical resection is an important prognostic factor, and patients can achieve long⁃term survival after total tumor resection. However, tumors in deep location such as brain stem and optic pathway cannot be completely removed by surgery. Chemotherapy is the first choice of adjuvant treatment when the clinical symptoms of pLGG worsen or imaging progress. In recent years, in addition to traditional chemotherapy, the development and application of targeted therapy drugs have also made great progress. This article reviews the research progress and challenges of chemotherapy and targeted therapy of pLGG, in order to provide guidance for clinical practice.
DOI: 10.3969/j.issn.1672⁃6731.2024.09.003
DOI: 10.3969/j.issn.1672⁃6731.2024.09.003
Keywords
Glioma; Antineoplastic combined chemotherapy protocols; Angiogenesis inhibitors; Molecular targeted therapy; Child; Review
This work is licensed under a Creative Commons Attribution 3.0 License.